---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-23-008448"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T04:31:26.023692+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# VolitionRx reports 185% revenue increase in 9M 2023; FDA 510(k) pathway for NETs

## Summary
- Revenue for first nine months 2023 was $531k, up 185% YoY; Nu.Q Vet Cancer Test revenue grew ~5x.
- Cash and equivalents $10.8M as of Sep 30, 2023, roughly flat vs year-end 2022.
- Post-quarter: Walloon funding approved for ~$6M; expects $13M milestone payments from Heska.
- FDA agreed to traditional 510(k) pathway for Nu.Q NETs test following Q-Sub process.
- Launched Nu.Q Vet Test in UK/Ireland via NationWide Laboratories and Veterinary Pathology Group.

## SEC filing metadata
- accession: 0001477932-23-008448
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793223008448/0001477932-23-008448-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793223008448/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-23-008448
- JSON: https://secwatch.observer/filing/0001477932-23-008448.json
- Plain text: https://secwatch.observer/filing/0001477932-23-008448.txt

## Key facts
- Earnings Releases
  VOLITIONRX LTD reported the third quarter ended September 30, 2023 results: revenue $531,000.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $531,000
  - Result: reported results
  source text: over the prior year period, reflecting sales of the reference kits through our global, regional and local supply agreements. Additionally, total year-to-date revenue was $531,000, a 185% increase compared to the comparable period of 2022. We believe that these results demonstrate steady growth, but not yet the “ramp” in revenues that we anticipate. We
  evidence_url: https://www.sec.gov/Archives/edgar/data/93314/000147793223008448/0001477932-23-008448-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.